Prognostic Significance and Diagnostic Value of Overexpressed lncRNA PVT1 in Colorectal Cancer

被引:8
|
作者
Pan, Xuefeng [1 ]
Cheng, Rui [1 ]
Zhu, Xiaoshan [2 ]
Cai, Fengbo [2 ]
Zheng, Guobao [1 ]
Li, Juntang [2 ]
Gao, Chunfang [2 ]
机构
[1] 989 Hosp Peoples Liberat Army, Dept Oncol, Luoyang 471031, Peoples R China
[2] 989 Hosp Peoples Liberat Army, Inst Anal Colorectal Surg, Luoyang 471031, Peoples R China
关键词
lncRNA; lncRNA PVT1; colorectal cancer; expression; prognosis; LONG NONCODING RNA; CELL-GROWTH; EXPRESSION; STATISTICS; AMPLIFICATION; PROGRESSION; BIOMARKER;
D O I
10.7754/Clin.Lab.2019.190412
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: The aim of this study is to investigate the expression of lncRNA PVT1 in CRC tissue compared to adjacent normal tissues, and reveal the association between lncRNA PVT1 expression level and the clinicopathological characteristics of patients with CRC. Methods: We detected the lncRNA PVT1 relative expression of cancerous tissues in 130 patients with CRC by using real-time quantitative polymerase chain reaction. At the same time, we collected the clinicopathological and prognostic information. Results: IncRNA PVT1 was overexpressed in CRC tissues compared to paired-adjacent normal tissues and the high expression rate was 72.31%. High expression of lncRNA PVT1 predicts a later tumor stage (p = 0.001), poorer tissue differentiation (p = 0.019), and higher plasma CEA level (p = 0.043). Additionally, the lncRNA PVT1 expression was closely related to lymph node metastasis (N1/N2 vs. N0) and distant metastasis (M1 vs. M0) in CRC patients (p = 0.002; p = 0.003), but not to tumor T classification (p = 0.314). The result of prognostic analysis indicated that the 1-year and 3-year DFS of the lncRNA PVT1 low and high expression patients were 93.8% and 81.1%, 69.3% and 44.7%, respectively. The median DFS was 44 months in low expression group and 26 months in high expression group, with statistical significance (p = 0.021). COX multivariate analysis showed that TNM staging (III/IV vs. I/II: HR = 6.342, 95% CI: 2.994 - 13.433, p < 0.001) and the lncRNA PVT1 expression (high expression vs. low expression: HR = 3.744, 95% CI: 1.493 - 9.392, p = 0.005) was closely related to DFS in CRC patients. As with tumor TNM staging, lncRNA PVT1 expression was also an independent prognostic predictor of DFS. The proportion of lncRNA PVT1 high expression (fold change >= 1.725) was higher than that of elevated CEA (> 5 ng/mL) in different CRC stages, especially, there was a significant difference in stage I patients (X-2 = 41.717, p < 0.0001). Conclusions: The lncRNA PVT1 was over-expressed in CRC tissues, which indicated a poor prognosis. The lncRNA PVT1 expression is far higher than the plasma CEA level in the early stage patients, which has the potential diagnostic value for early stage CRC.
引用
收藏
页码:2279 / 2288
页数:10
相关论文
共 50 条
  • [31] Diagnostic and prognostic value of lncRNA cancer susceptibility candidate 9 in hepatocellular carcinoma
    Zeng, Yong-Lian
    Guo, Zhen-Ya
    Su, Hui-Zhao
    Zhong, Fu-Di
    Jiang, Ke-Qing
    Yuan, Guan-Dou
    WORLD JOURNAL OF GASTROENTEROLOGY, 2019, 25 (48) : 6902 - 6915
  • [32] lncRNA PVT1: a novel oncogene in multiple cancers
    Li, Ruiming
    Wang, Xia
    Zhu, Chunming
    Wang, Kefeng
    CELLULAR & MOLECULAR BIOLOGY LETTERS, 2022, 27 (01)
  • [33] Noncoding RNA PVT1 in osteosarcoma: The roles of lncRNA PVT1 and circPVT1
    Wu, Tingrui
    Ji, Ziyu
    Lin, Hao
    Wei, Bo
    Xie, Guohao
    Ji, Guangju
    Fu, Shijie
    Huang, Wenhua
    Liu, Huan
    CELL DEATH DISCOVERY, 2022, 8 (01)
  • [34] MTUS1 is a promising diagnostic and prognostic biomarker for colorectal cancer
    Cheng, Lin-Yao
    Huang, Mao-Sen
    Zhong, Hua-Ge
    Ru, Hai-Ming
    Mo, Si-Si
    Wei, Chun-Yin
    Su, Zi-Jie
    Mo, Xian-Wei
    Yan, Lin-Hai
    Tang, Wei-Zhong
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2022, 20 (01)
  • [35] Downregulation of lncRNA PVT1 inhibits proliferation and migration of mesothelioma cells by targeting FOXM1
    Fujii, Yutaro
    Amatya, Vishwa Jeet
    Kushitani, Kei
    Suzuki, Rui
    Kai, Yuichiro
    Kambara, Takahiro
    Takeshima, Yukio
    ONCOLOGY REPORTS, 2022, 47 (02)
  • [36] PVT1 Signaling Is a Mediator of Cancer Progression
    Derderian, Camille
    Orunmuyi, Akintunde T.
    Olapade-Olaopa, E. Oluwabunmi
    Ogunwobi, Olorunseun O.
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [37] Novel PBMC LncRNA signatures as diagnostic biomarkers for colorectal cancer
    Li, Zhaosheng
    Wang, Dongfeng
    Zhang, Wenjun
    Shi, Huina
    Zhu, Mingchen
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 253
  • [38] The Role of lncRNA PVT1 and hsa-miR-30a-3p in the Development of Gastric Cancer
    Chen, Wenliang
    Fan, Daguang
    Guo, Bo
    Liu, Shuang
    Li, Zhuo
    Duan, Junfang
    Fang, Changzhong
    Liu, Yingtao
    Chen, Lin
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2022, 52 (02) : 292 - 300
  • [39] lncRNA PVT1 silencing inhibits gastric cancer cells' progression via enhancing chemosensitivity to paclitaxel
    Naseri, Bahar
    Farsad-Akhtar, Nader
    Mardi, Amirhossein
    Baghbani, Elham
    Bornedeli, Soghra
    Asadi, Milad
    Shanehbandi, Dariush
    GENE, 2025, 932
  • [40] The prognostic value of lncRNA SNHG1 in cancer patients: a meta-analysis
    Dong, Bingzi
    Chen, Xian
    Zhang, Yunyuan
    Zhu, Chengzhan
    Dong, Qian
    BMC CANCER, 2019, 19 (01)